Atlas Trials

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Clinical trial NCT02495922 · COMPLETED

Trial details

NCT number
NCT02495922
Sponsor
University of Heidelberg Medical Center
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2015-06-01
Primary completion
2021-06-24
Enrollment
564

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.